LYMPHOMAS

Sonrotoclax shows promise as a new treatment for relapsed/refractory mantle cell lymphoma, achieving significant response rates in heavily pretreated patients.

A groundbreaking study reveals ctDNA testing outperforms traditional imaging in predicting outcomes for patients with large B-cell lymphoma, enhancing treatment strategies.

Epcoritamab shows promising results in treating relapsed follicular lymphoma, with FDA priority review for a groundbreaking combination therapy.

Allogene Therapeutics halts ALLO-647 trial in large B-cell lymphoma after a patient death raises safety concerns, impacting future research.

FDA prioritizes review of liso-cel, a groundbreaking CAR T-cell therapy for relapsed marginal zone lymphoma, promising improved patient outcomes.

A new risk model uses objective clinical data to predict cure or relapse in Hodgkin lymphoma, with future plans to guide treatment and survivorship care.

Andrew Evens, DO, MBA, MSc, discusses a modern way of stratifying risk in patients with early-stage Hodgkin lymphoma.

Andrew Evens, DO, MBA, MSc, discusses the HOLISTIC consortium, which aims to gather and harmonize global Hodgkin lymphoma data from clinical trials and registries.

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed or high-risk lymphoma.

Michael Green, PhD, discusses a new method of assessing lymphoma subtypes utilizing the tumor microenvironment.

A recent trial reveals that nivolumab combined with chemotherapy significantly improves survival rates in older patients with advanced Hodgkin lymphoma.

New study reveals mosunetuzumab and polatuzumab vedotin significantly improve outcomes for patients with relapsed large B-cell lymphoma, offering a chemotherapy-free option.

Christina Poh, MD, discusses the recent FDA approval of tafasitamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

Tafasitamab-cxix gains FDA approval for relapsed follicular lymphoma, showcasing significant progression-free survival benefits in combination therapy.

In an 8 to 1 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 STARGLO trial are not applicable to patients in the US with diffuse large B-cell lymphoma.

Yago Nieto, MD, PhD, discusses AFM13, how it works, and its effect as a bispecific antibody that targets CD30 and CD16.

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase inhibitors and degraders.

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

Bexobrutideg, a first-in-class Bruton’s tyrosine kinase degrader, has been granted orphan drug designation from the FDA in Waldenström macroglobulinemia.

David A. Russler-Germain, MD, PhD, discusses his path in oncology and the many advancements shaping lymphoma treatment today.

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.

SGX301 has led positive results in early-stage CTCL, with over 70% achieving treatment success in the phase 3 FLASH study.

Fixed-duration glofitamab combined with polatuzumab vedotin achieved high response rates and sustained remissions in heavily pretreated relapsed/refractory large B-cell lymphoma.